Shamburg News · 8-K filed Oct 19, 2026, 9:22 AM EDT

EyePoint Cuts Workforce 53%, Winds Down Wet AMD Phase 3 Trials to Focus on DME

EYPT · EyePoint, Inc.

  • Earnings
  • Other event
  • Financial statements
  • Materiality: high

On October 17, 2026, EyePoint's Board approved a strategic prioritization plan after topline results from the LUCIA Phase 3 wet AMD trial, which did not meet its primary non-inferiority endpoint. The plan includes concluding the pivotal wet AMD trials early and reducing the workforce by approximately 53%, with estimated annualized savings of about $30 million. The company estimates aggregate employee separation charges of approximately $9 million, mostly recognized in the fourth quarter of 2026, and reported preliminary cash, cash equivalents and short-term investments of approximately $118 million as of September 30, 2026.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 2.02, 2.05, 8.01, 9.01, accession 0001193125-26-424755.

Written from the filing by Shamburg Markets. Figures are as reported by the company.